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Obesity is increasingly associated with the transformation of monoclonal gammopathy of undetermined significance (MGUS)
into multiple myeloma (MM). Obesity, MGUS, and MM share common etiopathogenesis mechanisms including altered insulin
axis and the action of inflammatory cytokines. Consistent with this interconnection, metformin could predominantly exert
inhibition of these pathophysiological factors and thus be an attractive therapeutic option for MGUS. Despite the possible clinical
significance, only a limited number of epidemiological studies have focused on obesity as a risk factor for MGUS and MM. (is
review describes multiple biological pathways modulated by metformin at the cellular level and their possible impacts on the
biology of MGUS and its progression into MM.
1. Introduction
Brazilian studies have revealed a remarkable prevalence of
diabetes [1], obesity [2], and cancer [3] in adults over time
and with a progressive expansion in the last years. Diabetes
mellitus type 2 (DM2) and cancer share many risk factors,
especially obesity and metabolic syndrome, with potential
biological connections between the two diseases, as meta-
analysis data from prospective cohort studies suggest a
modest but consistent direct effect of bodymass index (BMI)
on the incidence of lymphoma, multiple myeloma, increased
risk of leukemia in adults [4–13], increased risk of mono-
clonal gammopathy of undetermined significance (MGUS)
transformation into MM [5, 12, 14], and increased risk of
death in MM patients [15]. Data linking obesity to myeloma
are the most convincing among hematologic malignancies,
based on their replication in most studies [16–18]. Although
metformin has been shown to modulate multiple biological
pathways at the cellular level [19], few studies have focused
on the effects of metformin on the biology of MGUS and the
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protection from MM transformation. Although MM ther-
apeutic approaches conferred remarkable progress in the last
decade, the mortality of this disease is still considerably high.
Moreover, the therapeutic approaches available following
relapse are not feasible in low-income countries and are
financially costly for the public health system [20, 21].
(erefore, low-cost drugs that have a positive impact on
prevention should be carefully studied as an attempt to avoid
MGUS into MM progression.
2. Discussion
2.1. Obesity in MM. (ree percent of the population above
50 and 5% above 70 years of age has MGUS [22]. (e in-
cidence of progression into myeloma, lymphoma, or amy-
loidosis among patients with MGUS is about 1% per year
[22]. MGUS and MM share common risk factors that in-
clude occupational exposure to benzene and pesticides
[23, 24], advanced age [25], African ancestry [26, 27], and
male gender [25]. Recent evidence suggests common genetic
susceptibility to MM and MGUS [28–30] but still require
further studies. It should be noted that, in recent years, there
is growing evidence that obesity acts as a risk factor for the
occurrence of MM [4, 16–18, 31, 32]. In addition, obesity
affects the transformation of MGUS into MM [12, 33, 34].
From the epidemiological point of view, there are pro-
spective as well as meta-analyses data that support the as-
sociation between increased BMI and increased risk of
developing hematological malignancies [4, 9, 15, 35–37].
However, the role of confounder factors for this association
such as dietary habits, physical activity, and/or antidiabetic
therapy is largely unknown [38].
(e modified insulin signaling axis [32–35], the release
of adipokines [36–41], and lastly, low-grade chronic in-
flammation [34, 42] are plausible molecular mechanisms for
the association between obesity and hematological neo-
plasms. Leptin in combination with bone marrow micro-
environment cytokines, for example, interleukine-6 (IL-6),
insulin-like growth factor-1 (IGF-1), vascular endothelial
growth factor (VEGF), and TNF-alpha lead to adipocyte
differentiation of bone marrow mesenchymal stromal cells
(BM-MSCs), thus contributing to an increase in the adipose
marrow tissue [39, 40]. (erefore, all these mediators
negatively affect hematopoiesis and subsequently lead to the
remodeling of the bone marrow microenvironment that is
observed in obesity which favors the growth of cells neo-
plasms in bone marrow (BM) [37–39]. Likewise, IGF-1 and
IL-6 receptors show JAK-independent synergistic effects on
the induction of MM cell growth [41]. IGF-1 is an endocrine
factor produced and secreted by bone marrow stromal cells
(BMSC), bone endothelial cells, and osteoblasts that pro-
motes the homing, growth, and survival of myeloma cells in
the bone marrow environment, both dependent and inde-
pendent of IL-6 [42]. (e binding of the ligand to the IGF-1
receptor (IGF-1R) via the tyrosine kinase (TK) domain
activates the phosphoinositide 3-kinases/protein kinase B
(PI3K/Akt) [43, 44] and mitogen-activated protein/extracel-
lular signal-regulated kinases (MAPK/MEK/ERK) signaling
pathways [43, 44]. Indeed, IGF-1 mediates multiple effects on
MMcells through different signal transduction pathways. IGF-
1 binding to IGF-1R triggers tyrosine kinase, resulting in
activation of PI3K/Akt and RAS/RAF/MEK-ERK. PI3K/Akt is
involved mainly in the antiapoptotic effects, whereas the
MEK-ERK regulates cell cycle and proliferation. In addition to
these main pathways, IGF-IR is able to activate the Janus
kinases/signal transducer and activator of transcription pro-
teins (JAK/STAT) pathway and Wnt and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) sig-
naling [45] IGF-1 induces VEGF production in MM cells
through theMEK/ERK pathway, which increases angiogenesis
in the BM [46, 47]. IL-6 is a cytokine with pleiotropic effects in
hematopoietic and nonhematopoietic cells [39] with prog-
nostic value in MM [48, 49]. IL-6 is mostly secreted by the
BMSC, and its production and secretion are enhanced by the
adhesion between MM cells and BMSC, via NFkB [39]. VEGF
and IL-6 showmutual stimulation inMM, in whichVEGF acts
as a paracrinemediator that supportsMM cell growth through
the increase of IL-6 secretion by BMSCs and microvascular
endothelial cells. IL-6, in turn, may stimulate VEGF secretion
in a subset of myeloma cells, indirectly promoting angio-
genesis [50, 51]. Following binding to its receptor, IL-6 is able
to trigger the activation of the MEK/MAPK [52], JAK/STAT
[53], and PI3K/AKT signaling pathways [54].
Another essential signaling pathway that correlates with
the development of myeloma bone disease (MBD) is the
receptor activator of nuclear factor κB (RANK)/ligand of
RANK (RANKL) pathway, which stimulates the signals via
NF-κB and MAPK pathway providing the development,
maturation, and differentiation of osteoclast precursors [55].
(ese factors stimulate cell surface receptors and signaling
through JAK/STATs, MAPK, and PI3Kmolecules frequently
dysregulated in neoplastic cells [56].
Obesity and myeloma share signaling pathways that
upregulate insulin, IGF-1, leptin, and inflammatory cytokines,
raising the risk of malignant transformation [57, 58]. Con-
sonant with this, a drug that potentially inhibits these pathways
could be interesting as a therapeutic alternative in MGUS
consequently being associated with a lower risk to developMM
[34]. (e malignant transformation of a post-GC B cell or
plasma cell into MGUS and consequently into MM requires
both an initiating genetic event and multiple secondary genetic
events [59, 60]. (e malignant evolution of MGUS is mediated
by structural and functional alterations of the tumor-associated
stromal cells, producing in BM microenvironment that acts as
an essential partner in carcinogenesis and hence can be a new
target for therapy in early disease stages [59].
2.2. Metformin as a Preventive Drug in MM. (e Diabetes
Prevention Program (DPP) study showed that metformin
constantly reduced body weight over time, which could
explain the diabetes prevention effects of the drug. Met-
formin also significantly improved fasting insulin and
proinsulin and other adiposity parameters such as BMI,
waist circumference, and waist-hip ratio [61].
Epidemiological and preclinical research studies indicate
that metformin is a potential therapeutic target in patients with
leukemia [62, 63], lymphomas [63–65], and multiple myeloma
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[33, 34, 66–68]. It is expected that the diverse pleiotropic effects
of the drug act on multiple targets, specifically in myeloma, in
which there is a strong interaction between the clonal plasma
cells and the BM microenvironment [69] (Figure 1).
Metformin might conduct to systemically reduce the
levels of proinflammatory soluble mediators (e.g., IL-6 and
IGF-1) [70]. A recent study showed metformin specifically
decreased IL-6R expression, which is mediated via AMPK,
mTOR, as well as displaying an isolated and synergistic
effect with common antimyeloma drugs. Intriguingly, IL-
6R can serve as a biomarker for metformin action in
multiple myeloma [70]. Besides, it promotes appropriate
direction and intensity, antitumor immunity-related
metabolic checkpoints not solely in Tcells, cancer cells, and
associated immune suppressor cells of the microenviron-
ment; furthermore, it might interfere with the gut
microbiota and its systemic impacts on body metabolism
[71].
Finally, metformin influences bone turnover because it
activates AMP-activated protein kinase (AMPK), which, in
turn, acts as a negative regulator of RANKL in the
differentiation of osteoclasts. Furthermore, metformin
might also significantly suppress bone resorption [72, 73].
New epidemiological and preclinical research points to
metformin as a potential therapeutic target in patients with
multiple myeloma [5, 12, 33, 34, 68]. Although epidemiological
studies have reasonably and consistently reported reducedMM
incidence and/or mortality in diabetic patients who receive
metformin [74–78], many sampled their case study retro-
spectively from the hospital or clinical registries rather than
population-based registries, restricting external validity and
inserting potential selection biases. Some studies did not ex-
clude individuals with a prior cancer diagnosis, thus presenting
a possible reverse causation bias. Many studies included pa-
tients exposed to various treatments for diabetes, complicating
the analysis of metformin associations. Self-reporting of crucial
data such as concomitant medication use and cancer risk
factors such as obesity, tobacco use, and family history may
have provided exposure biases. Moreover, research of met-
formin benefit markers will demand to include essential host
factors such as circulating insulin and glucose levels, obesity,
and expression of OCT1 receptors in the liver and the tumor
Metformin direct/indirect effects










































Figure 1: Figure modified from [32]. Overview of cellular and tissue mechanisms of metformin on inhibiting plasm cell growth. Metformin
inhibits at tissue level: the inflammation caused by increases in circulating levels of leptin, insulin, IGF, IL-6, IL-1, and VGFR, driving by
adipocyte differentiation of bone marrow mesenchymal stromal cells (AD-MSCs); and a cellular level inhibits mitochondria complex I,
stimulates the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, and/or inhibits the insulin signaling
pathway. ACC, acetyl-CoA carboxylase; EMT, epithelial-mesenchymal transition; IGF, insulin growth factor; IGF-1, insulin-like growth
factor-1; IGF-1R, insulin-like growth factor-1 receptor; IR, insulin receptor; IL-1, interleukin 1; IL-6, interleukin-6, OCT1, organic cation
transporter 1; VGFR, endothelial growth factor.
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[79]. Additionally, tumor cells’ characteristics such as receptors
(insulin/IGF1) [57, 80] and pathway proteins (PI3K/mTOR,
LKB1, and TSC2) [81, 82] expressionmight potentially mediate
these indirect, host-mediated effects and any direct effects that
are extremely important.
Currently, there are a reduced number of epidemio-
logical studies focused on obesity as a risk factor for MGUS
and MM, notwithstanding the potential clinical importance
of obesity in myeloma [83]. Obesity and DM2 are risk factors
for myeloma that make metformin a potential protective
therapy in the evolution of the natural history of the disease
[12, 34].
3. Conclusion
Assuming that 3% of adults over the age of 50 have MGUS
and the increasing numbers of diabetes and obesity in the
world population, less toxic approaches are needed to
minimize the chances of MGUS to MM progression. An-
tidiabetic drugs such asmetformin are low-cost and safe, and
studies have demonstrated their potentially protective roles
in cancer, MM, and MGUS to MM progression. Interven-
tions with minor results may have a meaningful influence on
the cumulative disease load. Considering the pleiotropic
effects (direct and indirect) of metformin on the bone
marrow milieu, it is essential to investigate the mechanisms
involved in the preventive effects of the drug in the pro-
gression of multiple myeloma, in order to indicate its proper
use in this context.
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